Patents Examined by Jennifer Graser
  • Cell-permeabilising peptides and polypeptides for microbial cells
    Patent number: 8586709
    Abstract: Signal peptides and polypeptides from Methanobrevibacter ruminantium, a methanogenic archaea present in ruminants. Methods of using these peptides to permeabilise microbial cells, particularly M. ruminantium strain M1? (DSM 1093).
    Type: Grant
    Filed: September 25, 2008
    Date of Patent: November 19, 2013
    Assignee: Pastoral Greenhouse Research Limited
    Inventors: Graeme Trevor Attwood, William John Kelly, Eric Heinz Altermann
  • Detection kit containing a novel recombinant 15-kDA polypeptide useful for detecting human infection with
    Patent number: 8580271
    Abstract: Disclosed are the cloning and expression of a novel antigen of Bartonella henselae. The recombinant polypeptide is found to be highly immunogenic and is useful as a diagnostic test antigen. The polypeptide of the present invention provides the basis of a diagnostic assay that is sensitive, rapid and accurate diagnosis of infection with Bartonella henselae using patient's sera. Disclosed also are the ELISA for both IgG and IgM and allows diagnosis of early and late infection.
    Type: Grant
    Filed: August 17, 2012
    Date of Patent: November 12, 2013
    Assignee: Medical Diagnostic Laboratories, LLC
    Inventors: John G. Hoey, Lisa P. Huang, Martin E. Adelson, Eli Mordechai
  • Methods, devices, kits and compositions for detecting roundworm
    Patent number: 8580518
    Abstract: Methods, devices, kits and compositions for detecting the presence or absence of roundworm in a fecal sample are disclosed herein. The methods, devices, kits and compositions of the present invention may be used to confirm the presence or absence of roundworm in a fecal sample from a mammal that may also be infected with one or more of hookworm, whipworm, and heartworm. Confirmation of the presence or absence of roundworm in the mammal may be made, for example, for the purpose of selecting an optimal course of treating the mammal and/or for the purpose of determining whether the mammal has been rid of the infection after treatment has been initiated.
    Type: Grant
    Filed: May 18, 2009
    Date of Patent: November 12, 2013
    Assignees: IDEXX Laboratories, Inc., Divergence, Inc.
    Inventors: David Allen Elsemore, Laurie A. Flynn, Jinming Geng, Michael Crawford
  • Monoclonal antibodies that neutralize anthrax toxins
    Patent number: 8574853
    Abstract: The present invention relates to monoclonal antibodies that bind or neutralize anthrax lethal factor (LF), edema factor (EF), and/or protective antigen (PA). The invention provides such antibodies, fragments of such antibodies retaining anthrax toxin-binding ability, fully human or humanized antibodies retaining anthrax toxin-binding ability, and pharmaceutical compositions including such antibodies. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. Additionally, the invention provides for prophylactic, therapeutic, and diagnostic methods employing the antibodies and nucleic acids of the invention.
    Type: Grant
    Filed: December 2, 2011
    Date of Patent: November 5, 2013
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Zhaochun Chen, Robert H. Purcell, Suzanne U. Emerson, Stephen H. Leppla, Mahtab Moayeri
  • Peptides and methods for the detection of Lyme disease antibodies
    Patent number: 8568989
    Abstract: The invention provides compositions (e.g., peptide compositions) useful for the detection of antibodies that bind to Borrelia antigens. The peptide compositions comprise polypeptide sequences comprising variants in the IR6 domain of the Borrelia VlsE protein. The invention also provides devices, methods, and kits comprising such peptide compositions and useful for the detection of antibodies that bind to Borrelia antigens and the diagnosis of Lyme disease.
    Type: Grant
    Filed: November 17, 2010
    Date of Patent: October 29, 2013
    Assignee: Abaxis, Inc.
    Inventors: Rajesh K. Mehra, Kenneth P. Aron, Dennis M. Bleile
  • Lactic acid bacteria and their use in swine direct-fed microbials
    Patent number: 8563295
    Abstract: TRFs useful for identifying strains of interest are provided. A method of identifying one or more strain that can be used as a direct-fed microbial is also provided. One or more strain identified by the method is additionally provided. A method is also provided for administering to an animal an effective amount of the one or more strain. Additionally provided is an isolated strain chosen from at least one of Lactobacillus acidophilus strain PlB c6 (NRRL B-50103), Lactobacillus salivarius strain o246e 33w (NRRL B-50102), Pediococcus acidilactici strain o246e 42 (NRRL B-50171), and Pediococcus acidilactici strain PlJ e3 (NRRL B-50101). An isolated strain having all of the identifying characteristics of one of the strains listed above is also provided. One or more strain can be administered as a direct-fed microbial to an animal. Methods of preparing a direct-fed microbial are also provided.
    Type: Grant
    Filed: January 12, 2010
    Date of Patent: October 22, 2013
    Assignee: DuPont Nutrition Biosciences ApS
    Inventors: Mari Ellen Davis, Joshua Rehberger, Charles Maxwell, Thomas Rehberger, Mike King
  • Bacteriocin based methods to control lactic acid bacterial growth
    Patent number: 8563293
    Abstract: The present invention relates to compositions and methods for protection against bacterial contamination. The invention provides bactericidal yeast expressing bacteriocin proteins and methods of using the bactericidal yeast.
    Type: Grant
    Filed: November 23, 2009
    Date of Patent: October 22, 2013
    Assignee: Southern Illinois University Edwardsville
    Inventor: Ronald E. Worthington
  • Phosphotriesterase from agrobacterium radiobacter P230
    Patent number: 8557547
    Abstract: The present invention provides enzymes capable of hydrolysing organophosphate (OP) molecules. In particular, the invention provides a phosphotriesterase enzyme identified from an Agrobacterium radiobacter strain isolated from soil that hydrolyses OP pesticides, and the gene encoding that enzyme. The invention also provides mutants of the identified phosphotriesterase enzyme which have altered substrate specificity. The use of these enzymes in bioremediation strategies is also provided.
    Type: Grant
    Filed: October 12, 2012
    Date of Patent: October 15, 2013
    Assignee: Commonwealth Scientific and Industrial Research Organisation
    Inventors: Irene Horne, Tara Sutherland, Rebecca Harcourt, Robyn Russell, John Oakeshott
  • High-throughput in vitro translation (cell-lysate based) assay for detecting quorum sensing signals
    Patent number: 8546071
    Abstract: A cell-lysate extract based assay reagent for detecting quorum sensing signals is generally provided, along with methods of making and using the same. The assay reagent generally includes a cell-lysate extract formed from a biosensor bacterium (e.g., Agrobacterium tumefaciens NTL4 (pCF218)(pCF372)) and a detecting substrate (e.g., an absorbance-based or luminescence-based substrate). The cell-lysate extract can be prepared by (1) disrupting the cell membranes of the biosensor bacterium to release the cellular components into a solution, (2) centrifuging the resulting solution, and (3) removing the resulting supernatant solution.
    Type: Grant
    Filed: July 28, 2008
    Date of Patent: October 1, 2013
    Assignee: University of South Carolina
    Inventors: Alan W. Decho, Tomohiro Kawaguchi, Yung-pin Chen
  • Potency test for vaccine formulations
    Patent number: 8546149
    Abstract: The invention relates to certain methods for the determination of an antigen content of a first antigen in a mixture comprising two or more antigens. The invention also relates to a potency test for an antigen in a combination vaccine. The method allows the determination of the antigen content in a mixture additionally comprising antibodies that are capable of binding with the antigen.
    Type: Grant
    Filed: September 3, 2010
    Date of Patent: October 1, 2013
    Assignees: Intervet Inc., Intervet International B.V.
    Inventors: Michelle Allen, Mark Garrett, Urs Peter Bruderer, Martinus Antonius Johannes Thijssen
  • Group B polypeptides, nucleic acids and therapeutic compositions and vaccines thereof
    Patent number: 8529912
    Abstract: This invention provides an isolated nucleic acid encoding a polypeptide comprising amino acid sequences of a streptococcal matrix adhesion E (EmaE) polypeptide. Antibodies to the EmaE polypeptide and immunogenic fragments thereof are also provided. This invention provides pharmaceutical compositions, immunogenic compositions, vaccines, and diagnostic and therapeutic methods of use of the isolated polypeptide, antibodies thereto, and nucleic acids.
    Type: Grant
    Filed: February 18, 2011
    Date of Patent: September 10, 2013
    Assignees: St. Jude Children's Reseach Hospital, University of Utah Research Foundation
    Inventors: Elizabeth Adderson, John Bohnsack
  • Compositions and methods for treatment of microbial infections
    Patent number: 8518416
    Abstract: The present invention relates to methods and compositions for treatment of microbial infections and for the enhancement of resistance to infection. The invention comprises administration of an effective amount of a protein isolated from bacterial lysate compositions for the treatment of pathological conditions of microbial infections. The present invention can also be used to enhance the immune system to prevent infections by the administration of an effective amount of the compositions.
    Type: Grant
    Filed: October 24, 2011
    Date of Patent: August 27, 2013
    Assignee: Immunology Laboratories, Inc.
    Inventors: Jiri Pillich, John C. Balcarek
  • Human anti-It-2 antibodies derived from transgenic xenomouse
    Patent number: 8491907
    Abstract: The invention described herein provides for human antibodies produced in non-human animals that specifically bind to lipopolysaccharide (LPS) from strains Fisher Devlin (International Serogroups) It-2 (011), It-3 (02), It-4 (01), It-5 (010), It-6 (07), PA01 (05), 170003 (02), IATS016 (02/05), and 170006 (02). The invention further provides methods for making the antibodies in a non-human animal, expression of the antibodies in cell lines including hybridomas and recombinant host cell systems. Also provided are kits and pharmaceutical compositions comprising the antibodies and methods of treating or preventing pseudomonas infection by administering to a patient the pharmaceutical compositions described herein.
    Type: Grant
    Filed: July 13, 2010
    Date of Patent: July 23, 2013
    Assignee: Amgen, Inc.
    Inventor: John R. Schreiber
  • Protease-stable, cell wall-lysing enzymes
    Patent number: 8492519
    Abstract: The present invention relates to a modified polypeptide with a biological activity to lyse cell walls of bacteria, wherein the polypeptide has no caspase, clostripain, enterokinase, factor Xa, granzyme B, staphylococcus peptidase I (V8 Protease), plasmin, streptopain, bacillolysin and/or thrombin cleavage site. The invention further relates to nucleic acids with a sequence encoding a polypeptide according to the present invention.
    Type: Grant
    Filed: August 19, 2008
    Date of Patent: July 23, 2013
    Assignees: Hyglos Invest GmbH, bioMérieux S.A.
    Inventors: Holger Grallert, Michael Forchheim
  • Compositions and methods for treating of microbial infections
    Patent number: 8481053
    Abstract: The present invention relates to methods and compositions for treatment of microbial infections and for the enhancement of resistance to infection. The invention comprises administration of an effective amount of bacterial lysate compositions for the treatment of pathological conditions of microbial infections. The present invention can also be used to enhance the immune system to prevent infections by the administration of an effective amount of the compositions.
    Type: Grant
    Filed: August 30, 2011
    Date of Patent: July 9, 2013
    Assignee: Immunology Laboratories, Inc.
    Inventors: Jiri Pillich, John C. Balcarek
  • whole-cell vaccine composition
    Patent number: 8465754
    Abstract: An objective of the present invention is to provide a whole-cell bacterial vaccine composition for preventing whooping cough caused by Bordetella parapertussis, comprising whole cells, whole-cell homogenate, or cell lysate of B. parapertussis as an immunogen, and methods for producing them.
    Type: Grant
    Filed: May 28, 2008
    Date of Patent: June 18, 2013
    Assignee: Kitasato Daiichi Sankyo Vaccine Co., Ltd.
    Inventors: Mineo Watanabe, Eiji Komatsu
  • Diagnose of mycobacterial infections by determination of IFN-gamma
    Patent number: 8455201
    Abstract: The present invention provides a method for diagnosing a mycobacterial infection in a subject, involving the following steps: (i) collection of a sample from the subject; (ii) incubation of the sample from (i) with an antigen preparation for 12 hours or less; and (iii) analysis of ?-IFN in the sample from (ii). The invention also provides a diagnostic kit for use in such a method.
    Type: Grant
    Filed: August 14, 2007
    Date of Patent: June 4, 2013
    Assignee: The Pirbright Institute
    Inventors: Jayne Hope, Paul Sopp, Chris Howard
  • Proteins with repetitive bacterial-Ig-like (Big) domains present in species
    Patent number: 8445658
    Abstract: The invention relates to three isolated DNA molecules that encode for proteins, BigL1, BigL2 and BigL3, in the Leptospira sp bacterium which have repetitive Bacterial-Ig-like (Big) domains and their use in diagnostic, therapeutic and vaccine applications. According to the present invention, the isolated molecules encoding for BigL1, BigL2 and BigL3 proteins are used for the diagnosis and prevention of infection with Leptospira species that are capable of producing disease in humans and other mammals, including those of veterinary importance.
    Type: Grant
    Filed: June 15, 2012
    Date of Patent: May 21, 2013
    Assignees: The United States of America represented by the Department of Veterans Affairs, The Regents of the University of California, Cornell Research Foundation, Inc., Fundação Oswaldo Cruz—Fiocruz
    Inventors: Albert I. Ko, Mitermayer Galvão Reis, Julio Henrique Rosa Croda, Isadora Cristina Siqueira, David A. Haake, James Matsunaga, Lee W. Riley, Michele Barocchi, Tracy Ann Young
  • Regulated expression of antigen and/or regulated attentuation to enhance vaccine immunogenicity and/or safety
    Patent number: 8445254
    Abstract: The invention relates to compositions and methods for making and using recombinant bacteria that are capable of regulated attenuation and/or regulated expression of one or more antigens of interest.
    Type: Grant
    Filed: November 10, 2009
    Date of Patent: May 21, 2013
    Assignees: The Arizona Board of Regents for and on Behalf of Arizona State University, The Washington University
    Inventors: Roy Curtiss, III, Shifeng Wang, Soo-Young Wanda, Wei Kong
  • Probiotic strain and antimicrobial peptide derived therefrom
    Patent number: 8444998
    Abstract: A strain of Enterococcus mundtii has probiotic qualities. The strain of E. mundtii (ST4SA) produces an antimicrobial peptide which exhibits antimicrobial activity against a broad range of bacteria. An isolated nucleotide sequence codes for the antimicrobial peptide (peptide ST4SA). A process is also provided for the production of a peptide which comprises cultivating Enterococcus mundtii strain ST4SA in a nutrient medium under micro-aerophilic conditions at a temperature of between 10° C. and 45° C., until a recoverable quantity of the peptide is produced, and recovering the peptide. The isolated peptide may be used as an antimicrobial agent in a liquid formulation or a gel formulation as a topical treatment and may also be used as an antimicrobial agent following encapsulation in a polymer.
    Type: Grant
    Filed: April 26, 2011
    Date of Patent: May 21, 2013
    Assignee: CIPLA Medpro Research and Development (Pty) Ltd
    Inventors: Leon Milner Theodore Dicks, Svetoslav Dimitrov Todorov, Hendriette Knoetze, Marelize Brink